nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—pancreatic cancer	0.568	1	CbGaD
Gliclazide—ALB—Erlotinib—pancreatic cancer	0.0373	0.216	CbGbCtD
Gliclazide—ALB—Irinotecan—pancreatic cancer	0.0337	0.195	CbGbCtD
Gliclazide—ALB—Fluorouracil—pancreatic cancer	0.0323	0.187	CbGbCtD
Gliclazide—CYP2C19—Tamoxifen—pancreatic cancer	0.0284	0.165	CbGbCtD
Gliclazide—CYP2C9—Tamoxifen—pancreatic cancer	0.0236	0.137	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—pancreatic cancer	0.0174	0.101	CbGbCtD
Gliclazide—Glipizide—PPARG—pancreatic cancer	0.00074	1	CrCbGaD
Gliclazide—VEGFA—islet of Langerhans—pancreatic cancer	0.000364	0.194	CbGeAlD
Gliclazide—ALB—gall bladder—pancreatic cancer	0.000262	0.139	CbGeAlD
Gliclazide—KCNJ11—islet of Langerhans—pancreatic cancer	0.000261	0.138	CbGeAlD
Gliclazide—VEGFA—pancreas—pancreatic cancer	0.000256	0.136	CbGeAlD
Gliclazide—ABCC8—islet of Langerhans—pancreatic cancer	0.00024	0.128	CbGeAlD
Gliclazide—KCNJ11—pancreas—pancreatic cancer	0.000183	0.0973	CbGeAlD
Gliclazide—ABCC8—pancreas—pancreatic cancer	0.000169	0.0896	CbGeAlD
Gliclazide—Upper respiratory tract infection—Epirubicin—pancreatic cancer	9.69e-05	0.000614	CcSEcCtD
Gliclazide—Urticaria—Fluorouracil—pancreatic cancer	9.68e-05	0.000613	CcSEcCtD
Gliclazide—Headache—Sunitinib—pancreatic cancer	9.67e-05	0.000613	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—pancreatic cancer	9.65e-05	0.000611	CcSEcCtD
Gliclazide—Leukopenia—Docetaxel—pancreatic cancer	9.64e-05	0.000611	CcSEcCtD
Gliclazide—Body temperature increased—Fluorouracil—pancreatic cancer	9.63e-05	0.00061	CcSEcCtD
Gliclazide—Palpitations—Docetaxel—pancreatic cancer	9.52e-05	0.000603	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—pancreatic cancer	9.52e-05	0.000603	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—pancreatic cancer	9.49e-05	0.000601	CcSEcCtD
Gliclazide—Loss of consciousness—Docetaxel—pancreatic cancer	9.47e-05	0.0006	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—pancreatic cancer	9.41e-05	0.000596	CcSEcCtD
Gliclazide—Cough—Docetaxel—pancreatic cancer	9.4e-05	0.000595	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—pancreatic cancer	9.4e-05	0.000595	CcSEcCtD
Gliclazide—Hypersensitivity—Irinotecan—pancreatic cancer	9.37e-05	0.000593	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—pancreatic cancer	9.35e-05	0.000592	CcSEcCtD
Gliclazide—Convulsion—Docetaxel—pancreatic cancer	9.34e-05	0.000591	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—pancreatic cancer	9.3e-05	0.000589	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—pancreatic cancer	9.3e-05	0.000589	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—pancreatic cancer	9.28e-05	0.000588	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	9.22e-05	0.000584	CcSEcCtD
Gliclazide—Chest pain—Docetaxel—pancreatic cancer	9.17e-05	0.000581	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—pancreatic cancer	9.17e-05	0.000581	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—pancreatic cancer	9.17e-05	0.000581	CcSEcCtD
Gliclazide—Nausea—Sunitinib—pancreatic cancer	9.17e-05	0.000581	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—pancreatic cancer	9.16e-05	0.00058	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—pancreatic cancer	9.14e-05	0.000579	CcSEcCtD
Gliclazide—Asthenia—Irinotecan—pancreatic cancer	9.13e-05	0.000578	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—pancreatic cancer	9.12e-05	0.000577	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	9.11e-05	0.000577	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—pancreatic cancer	9.06e-05	0.000574	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—pancreatic cancer	9.04e-05	0.000572	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—pancreatic cancer	9.04e-05	0.000572	CcSEcCtD
Gliclazide—Hypersensitivity—Fluorouracil—pancreatic cancer	8.98e-05	0.000568	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—pancreatic cancer	8.97e-05	0.000568	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	8.97e-05	0.000568	CcSEcCtD
Gliclazide—Sweating—Epirubicin—pancreatic cancer	8.92e-05	0.000564	CcSEcCtD
Gliclazide—Asthenia—Gemcitabine—pancreatic cancer	8.89e-05	0.000563	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—pancreatic cancer	8.87e-05	0.000561	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.81e-05	0.000558	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—pancreatic cancer	8.8e-05	0.000557	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—pancreatic cancer	8.78e-05	0.000556	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—pancreatic cancer	8.77e-05	0.000555	CcSEcCtD
Gliclazide—Pruritus—Gemcitabine—pancreatic cancer	8.77e-05	0.000555	CcSEcCtD
Gliclazide—Infection—Docetaxel—pancreatic cancer	8.74e-05	0.000553	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—pancreatic cancer	8.72e-05	0.000552	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—pancreatic cancer	8.71e-05	0.000551	CcSEcCtD
Gliclazide—Diarrhoea—Irinotecan—pancreatic cancer	8.7e-05	0.000551	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—pancreatic cancer	8.68e-05	0.000549	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—pancreatic cancer	8.65e-05	0.000548	CcSEcCtD
Gliclazide—Nervous system disorder—Docetaxel—pancreatic cancer	8.62e-05	0.000546	CcSEcCtD
Gliclazide—Pruritus—Fluorouracil—pancreatic cancer	8.62e-05	0.000546	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—pancreatic cancer	8.61e-05	0.000545	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—pancreatic cancer	8.6e-05	0.000545	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—pancreatic cancer	8.58e-05	0.000543	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—pancreatic cancer	8.54e-05	0.000541	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	8.53e-05	0.00054	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—pancreatic cancer	8.5e-05	0.000538	CcSEcCtD
Gliclazide—Diarrhoea—Gemcitabine—pancreatic cancer	8.48e-05	0.000537	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—pancreatic cancer	8.46e-05	0.000536	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	8.43e-05	0.000534	CcSEcCtD
Gliclazide—Dizziness—Irinotecan—pancreatic cancer	8.41e-05	0.000533	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—pancreatic cancer	8.39e-05	0.000531	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—pancreatic cancer	8.37e-05	0.00053	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—pancreatic cancer	8.36e-05	0.00053	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—pancreatic cancer	8.36e-05	0.00053	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—pancreatic cancer	8.35e-05	0.000529	CcSEcCtD
Gliclazide—Diarrhoea—Fluorouracil—pancreatic cancer	8.34e-05	0.000528	CcSEcCtD
Gliclazide—CYP2C19—digestive system—pancreatic cancer	8.31e-05	0.0441	CbGeAlD
Gliclazide—Hypoaesthesia—Epirubicin—pancreatic cancer	8.31e-05	0.000526	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—pancreatic cancer	8.29e-05	0.000525	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—pancreatic cancer	8.25e-05	0.000522	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—pancreatic cancer	8.22e-05	0.000521	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—pancreatic cancer	8.22e-05	0.00052	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—pancreatic cancer	8.14e-05	0.000515	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—pancreatic cancer	8.12e-05	0.000514	CcSEcCtD
Gliclazide—Vomiting—Irinotecan—pancreatic cancer	8.09e-05	0.000512	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—pancreatic cancer	8.07e-05	0.000511	CcSEcCtD
Gliclazide—Dizziness—Fluorouracil—pancreatic cancer	8.06e-05	0.00051	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—pancreatic cancer	8.05e-05	0.000509	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—pancreatic cancer	8.03e-05	0.000508	CcSEcCtD
Gliclazide—Rash—Irinotecan—pancreatic cancer	8.02e-05	0.000508	CcSEcCtD
Gliclazide—Dermatitis—Irinotecan—pancreatic cancer	8.01e-05	0.000507	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.01e-05	0.000507	CcSEcCtD
Gliclazide—Headache—Irinotecan—pancreatic cancer	7.97e-05	0.000505	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—pancreatic cancer	7.95e-05	0.000504	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—pancreatic cancer	7.9e-05	0.0005	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—pancreatic cancer	7.89e-05	0.0005	CcSEcCtD
Gliclazide—Vomiting—Gemcitabine—pancreatic cancer	7.88e-05	0.000499	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—pancreatic cancer	7.86e-05	0.000498	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—pancreatic cancer	7.84e-05	0.000496	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—pancreatic cancer	7.82e-05	0.000495	CcSEcCtD
Gliclazide—Rash—Gemcitabine—pancreatic cancer	7.81e-05	0.000495	CcSEcCtD
Gliclazide—Dermatitis—Gemcitabine—pancreatic cancer	7.81e-05	0.000494	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—pancreatic cancer	7.8e-05	0.000494	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—pancreatic cancer	7.78e-05	0.000493	CcSEcCtD
Gliclazide—Headache—Gemcitabine—pancreatic cancer	7.76e-05	0.000492	CcSEcCtD
Gliclazide—Flushing—Epirubicin—pancreatic cancer	7.75e-05	0.000491	CcSEcCtD
Gliclazide—Vomiting—Fluorouracil—pancreatic cancer	7.75e-05	0.00049	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—pancreatic cancer	7.74e-05	0.00049	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—pancreatic cancer	7.74e-05	0.00049	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—pancreatic cancer	7.72e-05	0.000489	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.69e-05	0.000487	CcSEcCtD
Gliclazide—Rash—Fluorouracil—pancreatic cancer	7.68e-05	0.000486	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—pancreatic cancer	7.67e-05	0.000486	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—pancreatic cancer	7.67e-05	0.000485	CcSEcCtD
Gliclazide—Headache—Fluorouracil—pancreatic cancer	7.63e-05	0.000483	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—pancreatic cancer	7.61e-05	0.000482	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.59e-05	0.000481	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—pancreatic cancer	7.58e-05	0.00048	CcSEcCtD
Gliclazide—Nausea—Irinotecan—pancreatic cancer	7.56e-05	0.000478	CcSEcCtD
Gliclazide—Pain—Docetaxel—pancreatic cancer	7.52e-05	0.000476	CcSEcCtD
Gliclazide—Constipation—Docetaxel—pancreatic cancer	7.52e-05	0.000476	CcSEcCtD
Gliclazide—Chills—Epirubicin—pancreatic cancer	7.49e-05	0.000474	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—pancreatic cancer	7.46e-05	0.000472	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—pancreatic cancer	7.44e-05	0.000471	CcSEcCtD
Gliclazide—Nausea—Gemcitabine—pancreatic cancer	7.36e-05	0.000466	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—pancreatic cancer	7.31e-05	0.000463	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—pancreatic cancer	7.3e-05	0.000462	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—pancreatic cancer	7.27e-05	0.00046	CcSEcCtD
Gliclazide—Erythema—Epirubicin—pancreatic cancer	7.27e-05	0.00046	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—pancreatic cancer	7.25e-05	0.000459	CcSEcCtD
Gliclazide—Nausea—Fluorouracil—pancreatic cancer	7.24e-05	0.000458	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—pancreatic cancer	7.22e-05	0.000457	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—pancreatic cancer	7.2e-05	0.000456	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.19e-05	0.000455	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—pancreatic cancer	7.17e-05	0.000454	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—pancreatic cancer	7.16e-05	0.000453	CcSEcCtD
Gliclazide—Tension—Epirubicin—pancreatic cancer	7.13e-05	0.000452	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—pancreatic cancer	7.06e-05	0.000447	CcSEcCtD
Gliclazide—Back pain—Epirubicin—pancreatic cancer	7.03e-05	0.000445	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—pancreatic cancer	6.95e-05	0.00044	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—pancreatic cancer	6.95e-05	0.00044	CcSEcCtD
Gliclazide—Chills—Doxorubicin—pancreatic cancer	6.93e-05	0.000439	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—pancreatic cancer	6.9e-05	0.000437	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—pancreatic cancer	6.77e-05	0.000428	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—pancreatic cancer	6.74e-05	0.000427	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—pancreatic cancer	6.72e-05	0.000426	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—pancreatic cancer	6.72e-05	0.000426	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—pancreatic cancer	6.72e-05	0.000425	CcSEcCtD
Gliclazide—Agitation—Epirubicin—pancreatic cancer	6.68e-05	0.000423	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—pancreatic cancer	6.63e-05	0.00042	CcSEcCtD
Gliclazide—Tension—Doxorubicin—pancreatic cancer	6.6e-05	0.000418	CcSEcCtD
Gliclazide—Malaise—Epirubicin—pancreatic cancer	6.55e-05	0.000415	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—pancreatic cancer	6.53e-05	0.000414	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—pancreatic cancer	6.51e-05	0.000412	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—pancreatic cancer	6.5e-05	0.000412	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—pancreatic cancer	6.48e-05	0.00041	CcSEcCtD
Gliclazide—CYP2C9—digestive system—pancreatic cancer	6.44e-05	0.0342	CbGeAlD
Gliclazide—Palpitations—Epirubicin—pancreatic cancer	6.42e-05	0.000407	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—pancreatic cancer	6.39e-05	0.000404	CcSEcCtD
Gliclazide—Cough—Epirubicin—pancreatic cancer	6.34e-05	0.000402	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—pancreatic cancer	6.31e-05	0.000399	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—pancreatic cancer	6.3e-05	0.000399	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—pancreatic cancer	6.27e-05	0.000397	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—pancreatic cancer	6.24e-05	0.000395	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—pancreatic cancer	6.22e-05	0.000394	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—pancreatic cancer	6.22e-05	0.000394	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—pancreatic cancer	6.19e-05	0.000392	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—pancreatic cancer	6.19e-05	0.000392	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—pancreatic cancer	6.19e-05	0.000392	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—pancreatic cancer	6.18e-05	0.000391	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—pancreatic cancer	6.17e-05	0.00039	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.14e-05	0.000389	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—pancreatic cancer	6.11e-05	0.000387	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—pancreatic cancer	6.06e-05	0.000384	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—pancreatic cancer	6.05e-05	0.000383	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—pancreatic cancer	6.02e-05	0.000381	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—pancreatic cancer	6.02e-05	0.000381	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—pancreatic cancer	5.98e-05	0.000379	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—pancreatic cancer	5.94e-05	0.000376	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—pancreatic cancer	5.91e-05	0.000374	CcSEcCtD
Gliclazide—Infection—Epirubicin—pancreatic cancer	5.89e-05	0.000373	CcSEcCtD
Gliclazide—Cough—Doxorubicin—pancreatic cancer	5.87e-05	0.000372	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—pancreatic cancer	5.83e-05	0.000369	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—pancreatic cancer	5.82e-05	0.000368	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—pancreatic cancer	5.81e-05	0.000368	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—pancreatic cancer	5.81e-05	0.000368	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—pancreatic cancer	5.81e-05	0.000368	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—pancreatic cancer	5.79e-05	0.000367	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—pancreatic cancer	5.76e-05	0.000365	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—pancreatic cancer	5.73e-05	0.000363	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—pancreatic cancer	5.72e-05	0.000362	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—pancreatic cancer	5.72e-05	0.000362	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—pancreatic cancer	5.72e-05	0.000362	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—pancreatic cancer	5.71e-05	0.000361	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.69e-05	0.00036	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—pancreatic cancer	5.66e-05	0.000358	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—pancreatic cancer	5.6e-05	0.000354	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—pancreatic cancer	5.59e-05	0.000354	CcSEcCtD
Gliclazide—Rash—Docetaxel—pancreatic cancer	5.54e-05	0.000351	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—pancreatic cancer	5.54e-05	0.000351	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—pancreatic cancer	5.54e-05	0.000351	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—pancreatic cancer	5.53e-05	0.00035	CcSEcCtD
Gliclazide—Headache—Docetaxel—pancreatic cancer	5.51e-05	0.000349	CcSEcCtD
Gliclazide—Infection—Doxorubicin—pancreatic cancer	5.45e-05	0.000345	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.4e-05	0.000342	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—pancreatic cancer	5.38e-05	0.000341	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.37e-05	0.00034	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—pancreatic cancer	5.36e-05	0.00034	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—pancreatic cancer	5.36e-05	0.000339	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—pancreatic cancer	5.33e-05	0.000338	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—pancreatic cancer	5.33e-05	0.000337	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.31e-05	0.000336	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—pancreatic cancer	5.29e-05	0.000335	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—pancreatic cancer	5.27e-05	0.000334	CcSEcCtD
Gliclazide—Nausea—Docetaxel—pancreatic cancer	5.22e-05	0.000331	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—pancreatic cancer	5.22e-05	0.000331	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—pancreatic cancer	5.13e-05	0.000325	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.12e-05	0.000324	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—pancreatic cancer	5.11e-05	0.000324	CcSEcCtD
Gliclazide—Pain—Epirubicin—pancreatic cancer	5.07e-05	0.000321	CcSEcCtD
Gliclazide—Constipation—Epirubicin—pancreatic cancer	5.07e-05	0.000321	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5e-05	0.000317	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—pancreatic cancer	4.96e-05	0.000314	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	4.94e-05	0.000502	CbGpPWpGaD
Gliclazide—Paraesthesia—Doxorubicin—pancreatic cancer	4.93e-05	0.000312	CcSEcCtD
Gliclazide—ABCC8—Metabolism—DPYD—pancreatic cancer	4.92e-05	0.0005	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—pancreatic cancer	4.89e-05	0.00031	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—pancreatic cancer	4.89e-05	0.000309	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—pancreatic cancer	4.88e-05	0.000309	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.85e-05	0.000307	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—GLP1R—pancreatic cancer	4.85e-05	0.000493	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NOTCH1—pancreatic cancer	4.83e-05	0.000491	CbGpPWpGaD
Gliclazide—Dyspepsia—Doxorubicin—pancreatic cancer	4.83e-05	0.000306	CcSEcCtD
Gliclazide—ALB—Hemostasis—PPP2R5B—pancreatic cancer	4.8e-05	0.000488	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DPYD—pancreatic cancer	4.77e-05	0.000485	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—pancreatic cancer	4.74e-05	0.000482	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DTX4—pancreatic cancer	4.74e-05	0.000481	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GLI1—pancreatic cancer	4.74e-05	0.000481	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.74e-05	0.0003	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—pancreatic cancer	4.73e-05	0.0003	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	4.72e-05	0.00048	CbGpPWpGaD
Gliclazide—Urticaria—Epirubicin—pancreatic cancer	4.71e-05	0.000298	CcSEcCtD
Gliclazide—Pain—Doxorubicin—pancreatic cancer	4.69e-05	0.000297	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—pancreatic cancer	4.69e-05	0.000297	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—pancreatic cancer	4.69e-05	0.000297	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—pancreatic cancer	4.69e-05	0.000297	CcSEcCtD
Gliclazide—ABCC8—Metabolism—SLC2A2—pancreatic cancer	4.67e-05	0.000474	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—pancreatic cancer	4.65e-05	0.000473	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CG—pancreatic cancer	4.64e-05	0.000471	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—pancreatic cancer	4.62e-05	0.000469	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PPP2R5B—pancreatic cancer	4.61e-05	0.000468	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRP1—pancreatic cancer	4.61e-05	0.000468	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EGF—pancreatic cancer	4.58e-05	0.000466	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	4.57e-05	0.000464	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PPARG—pancreatic cancer	4.56e-05	0.000463	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SLC2A2—pancreatic cancer	4.53e-05	0.00046	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—pancreatic cancer	4.52e-05	0.000286	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.49e-05	0.000284	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—HEY2—pancreatic cancer	4.44e-05	0.000451	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—pancreatic cancer	4.41e-05	0.000448	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—pancreatic cancer	4.4e-05	0.000448	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—pancreatic cancer	4.39e-05	0.000446	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—pancreatic cancer	4.37e-05	0.000277	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—pancreatic cancer	4.36e-05	0.000276	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—pancreatic cancer	4.34e-05	0.000275	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—pancreatic cancer	4.34e-05	0.000275	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—GAST—pancreatic cancer	4.33e-05	0.00044	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—pancreatic cancer	4.28e-05	0.000435	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—pancreatic cancer	4.28e-05	0.000435	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—pancreatic cancer	4.26e-05	0.000269	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	4.2e-05	0.000427	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—pancreatic cancer	4.2e-05	0.000266	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MMP2—pancreatic cancer	4.19e-05	0.000425	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SCT—pancreatic cancer	4.11e-05	0.000417	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HEY1—pancreatic cancer	4.11e-05	0.000417	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—pancreatic cancer	4.08e-05	0.000414	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CD—pancreatic cancer	4.07e-05	0.000414	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—SRC—pancreatic cancer	4.07e-05	0.000413	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—pancreatic cancer	4.06e-05	0.000257	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—pancreatic cancer	4.04e-05	0.000256	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—pancreatic cancer	3.94e-05	0.000249	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—TGFB1—pancreatic cancer	3.93e-05	0.000399	CbGpPWpGaD
Gliclazide—Dizziness—Epirubicin—pancreatic cancer	3.92e-05	0.000248	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CCK—pancreatic cancer	3.92e-05	0.000398	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—NRAS—pancreatic cancer	3.91e-05	0.000397	CbGpPWpGaD
Gliclazide—Pruritus—Doxorubicin—pancreatic cancer	3.88e-05	0.000246	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—AKT1—pancreatic cancer	3.87e-05	0.000393	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.86e-05	0.000392	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CNR2—pancreatic cancer	3.82e-05	0.000388	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GLP1R—pancreatic cancer	3.82e-05	0.000388	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—pancreatic cancer	3.77e-05	0.000239	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TP53—pancreatic cancer	3.77e-05	0.000383	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCKAR—pancreatic cancer	3.76e-05	0.000382	CbGpPWpGaD
Gliclazide—Diarrhoea—Doxorubicin—pancreatic cancer	3.75e-05	0.000238	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—pancreatic cancer	3.74e-05	0.00038	CbGpPWpGaD
Gliclazide—Rash—Epirubicin—pancreatic cancer	3.74e-05	0.000237	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—pancreatic cancer	3.74e-05	0.000237	CcSEcCtD
Gliclazide—Headache—Epirubicin—pancreatic cancer	3.72e-05	0.000235	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—JAG2—pancreatic cancer	3.64e-05	0.00037	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—pancreatic cancer	3.63e-05	0.00023	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CD44—pancreatic cancer	3.61e-05	0.000367	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MEN1—pancreatic cancer	3.59e-05	0.000365	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—pancreatic cancer	3.56e-05	0.000362	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CB—pancreatic cancer	3.55e-05	0.000361	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—pancreatic cancer	3.53e-05	0.000359	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—pancreatic cancer	3.52e-05	0.000358	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—pancreatic cancer	3.52e-05	0.000223	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CD44—pancreatic cancer	3.5e-05	0.000356	CbGpPWpGaD
Gliclazide—Vomiting—Doxorubicin—pancreatic cancer	3.49e-05	0.000221	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GCG—pancreatic cancer	3.47e-05	0.000352	CbGpPWpGaD
Gliclazide—Rash—Doxorubicin—pancreatic cancer	3.46e-05	0.000219	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—pancreatic cancer	3.46e-05	0.000219	CcSEcCtD
Gliclazide—Headache—Doxorubicin—pancreatic cancer	3.44e-05	0.000218	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	3.43e-05	0.000349	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SHH—pancreatic cancer	3.43e-05	0.000348	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—pancreatic cancer	3.42e-05	0.000348	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH4—pancreatic cancer	3.4e-05	0.000346	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—pancreatic cancer	3.4e-05	0.000345	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IAPP—pancreatic cancer	3.38e-05	0.000344	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—pancreatic cancer	3.37e-05	0.000342	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GCG—pancreatic cancer	3.36e-05	0.000341	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—pancreatic cancer	3.26e-05	0.000206	CcSEcCtD
Gliclazide—ABCC8—Metabolism—STK11—pancreatic cancer	3.26e-05	0.000331	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTCH1—pancreatic cancer	3.25e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTHLH—pancreatic cancer	3.25e-05	0.00033	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.21e-05	0.000326	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—pancreatic cancer	3.21e-05	0.000326	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	3.17e-05	0.000322	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—STK11—pancreatic cancer	3.16e-05	0.000321	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—pancreatic cancer	3.15e-05	0.00032	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	3.14e-05	0.000319	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SST—pancreatic cancer	2.97e-05	0.000302	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAG1—pancreatic cancer	2.91e-05	0.000295	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SRC—pancreatic cancer	2.9e-05	0.000295	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH3—pancreatic cancer	2.89e-05	0.000294	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CD44—pancreatic cancer	2.87e-05	0.000292	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—pancreatic cancer	2.86e-05	0.000291	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SRC—pancreatic cancer	2.85e-05	0.000289	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—pancreatic cancer	2.8e-05	0.000285	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—pancreatic cancer	2.8e-05	0.000284	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—pancreatic cancer	2.79e-05	0.000284	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	2.79e-05	0.000283	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA1—pancreatic cancer	2.78e-05	0.000283	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CNR1—pancreatic cancer	2.74e-05	0.000279	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—pancreatic cancer	2.74e-05	0.000278	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—pancreatic cancer	2.72e-05	0.000276	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GCG—pancreatic cancer	2.65e-05	0.000269	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRSS1—pancreatic cancer	2.64e-05	0.000268	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—pancreatic cancer	2.59e-05	0.000264	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA2—pancreatic cancer	2.59e-05	0.000263	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—pancreatic cancer	2.54e-05	0.000259	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—pancreatic cancer	2.54e-05	0.000258	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGTR1—pancreatic cancer	2.53e-05	0.000257	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STK11—pancreatic cancer	2.49e-05	0.000253	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	2.43e-05	0.000247	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—pancreatic cancer	2.42e-05	0.000246	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—pancreatic cancer	2.4e-05	0.000244	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRSS1—pancreatic cancer	2.37e-05	0.000241	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—pancreatic cancer	2.36e-05	0.000239	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ARG2—pancreatic cancer	2.29e-05	0.000232	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—pancreatic cancer	2.28e-05	0.000232	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—pancreatic cancer	2.21e-05	0.000225	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMAD4—pancreatic cancer	2.18e-05	0.000222	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—pancreatic cancer	2.17e-05	0.00022	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRSS1—pancreatic cancer	2.16e-05	0.000219	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HES1—pancreatic cancer	2.13e-05	0.000216	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—pancreatic cancer	2.09e-05	0.000213	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CG—pancreatic cancer	2.06e-05	0.000209	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ARG2—pancreatic cancer	2.05e-05	0.000209	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—pancreatic cancer	2.04e-05	0.000207	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—pancreatic cancer	2e-05	0.000204	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMP—pancreatic cancer	2e-05	0.000203	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CG—pancreatic cancer	1.99e-05	0.000203	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—pancreatic cancer	1.99e-05	0.000202	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	1.95e-05	0.000198	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—pancreatic cancer	1.93e-05	0.000196	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	1.9e-05	0.000193	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ARG2—pancreatic cancer	1.87e-05	0.00019	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—pancreatic cancer	1.87e-05	0.00019	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—pancreatic cancer	1.84e-05	0.000187	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—pancreatic cancer	1.81e-05	0.000184	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—pancreatic cancer	1.8e-05	0.000183	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMP—pancreatic cancer	1.8e-05	0.000182	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—pancreatic cancer	1.78e-05	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC2—pancreatic cancer	1.78e-05	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—pancreatic cancer	1.77e-05	0.00018	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—pancreatic cancer	1.75e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	1.74e-05	0.000177	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—pancreatic cancer	1.74e-05	0.000177	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—pancreatic cancer	1.71e-05	0.000173	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.65e-05	0.000168	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.64e-05	0.000166	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—pancreatic cancer	1.64e-05	0.000166	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKBIA—pancreatic cancer	1.62e-05	0.000165	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EGF—pancreatic cancer	1.62e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GLP1R—pancreatic cancer	1.61e-05	0.000164	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH1—pancreatic cancer	1.61e-05	0.000163	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DPYD—pancreatic cancer	1.59e-05	0.000161	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—pancreatic cancer	1.58e-05	0.00016	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—pancreatic cancer	1.57e-05	0.00016	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—pancreatic cancer	1.56e-05	0.000159	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGF—pancreatic cancer	1.55e-05	0.000158	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—pancreatic cancer	1.53e-05	0.000155	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—pancreatic cancer	1.51e-05	0.000154	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A2—pancreatic cancer	1.5e-05	0.000153	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.49e-05	0.000151	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	1.48e-05	0.000151	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.48e-05	0.000151	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GLP1R—pancreatic cancer	1.45e-05	0.000147	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—pancreatic cancer	1.44e-05	0.000146	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.44e-05	0.000146	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DPYD—pancreatic cancer	1.42e-05	0.000145	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—pancreatic cancer	1.38e-05	0.00014	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—pancreatic cancer	1.36e-05	0.000138	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	1.35e-05	0.000137	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.35e-05	0.000137	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.34e-05	0.000136	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—pancreatic cancer	1.32e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.32e-05	0.000134	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.31e-05	0.000133	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.3e-05	0.000132	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.29e-05	0.000131	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—pancreatic cancer	1.25e-05	0.000127	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.23e-05	0.000125	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.22e-05	0.000124	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	1.21e-05	0.000123	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—pancreatic cancer	1.2e-05	0.000122	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.18e-05	0.00012	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.18e-05	0.000119	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD44—pancreatic cancer	1.17e-05	0.000118	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—pancreatic cancer	1.16e-05	0.000118	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.14e-05	0.000116	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.13e-05	0.000115	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCG—pancreatic cancer	1.12e-05	0.000114	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—pancreatic cancer	1.11e-05	0.000113	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—pancreatic cancer	1.08e-05	0.00011	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.07e-05	0.000109	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—pancreatic cancer	1.07e-05	0.000108	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STK11—pancreatic cancer	1.05e-05	0.000107	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—pancreatic cancer	1.05e-05	0.000106	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD44—pancreatic cancer	1.05e-05	0.000106	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—pancreatic cancer	1.04e-05	0.000106	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.02e-05	0.000104	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.02e-05	0.000103	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—pancreatic cancer	1e-05	0.000102	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCG—pancreatic cancer	1e-05	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.86e-06	0.0001	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—pancreatic cancer	9.78e-06	9.94e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—pancreatic cancer	9.66e-06	9.82e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—pancreatic cancer	9.65e-06	9.8e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—pancreatic cancer	9.61e-06	9.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD44—pancreatic cancer	9.54e-06	9.69e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STK11—pancreatic cancer	9.43e-06	9.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.34e-06	9.49e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—pancreatic cancer	9.32e-06	9.47e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—pancreatic cancer	9.31e-06	9.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—pancreatic cancer	9.28e-06	9.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.25e-06	9.4e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCG—pancreatic cancer	9.15e-06	9.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—pancreatic cancer	9.04e-06	9.18e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—pancreatic cancer	8.98e-06	9.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.85e-06	8.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—pancreatic cancer	8.65e-06	8.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—pancreatic cancer	8.63e-06	8.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STK11—pancreatic cancer	8.6e-06	8.74e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—pancreatic cancer	8.46e-06	8.59e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—pancreatic cancer	8.32e-06	8.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—pancreatic cancer	8.11e-06	8.24e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.07e-06	8.2e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—pancreatic cancer	7.99e-06	8.12e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—pancreatic cancer	7.85e-06	7.98e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—pancreatic cancer	7.64e-06	7.76e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—pancreatic cancer	7.61e-06	7.73e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—pancreatic cancer	7.4e-06	7.52e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—pancreatic cancer	7.39e-06	7.51e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—pancreatic cancer	7.35e-06	7.47e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—pancreatic cancer	7.34e-06	7.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—pancreatic cancer	7.1e-06	7.22e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—pancreatic cancer	7.07e-06	7.18e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.96e-06	7.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—pancreatic cancer	6.79e-06	6.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—pancreatic cancer	6.63e-06	6.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—pancreatic cancer	6.6e-06	6.7e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—pancreatic cancer	6.4e-06	6.5e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.24e-06	6.35e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—pancreatic cancer	6.24e-06	6.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—pancreatic cancer	6.02e-06	6.11e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—pancreatic cancer	6e-06	6.09e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	5.95e-06	6.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—pancreatic cancer	5.83e-06	5.92e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—pancreatic cancer	5.75e-06	5.84e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.69e-06	5.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	5.43e-06	5.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—pancreatic cancer	5.24e-06	5.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	5.23e-06	5.32e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—pancreatic cancer	5.08e-06	5.16e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—pancreatic cancer	5.04e-06	5.12e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	4.77e-06	4.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	4.56e-06	4.64e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—pancreatic cancer	4.52e-06	4.59e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—pancreatic cancer	4.39e-06	4.46e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	4.16e-06	4.23e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—pancreatic cancer	4.12e-06	4.19e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.94e-06	4.01e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.59e-06	3.65e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—pancreatic cancer	3.1e-06	3.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.78e-06	2.83e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.54e-06	2.58e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—pancreatic cancer	2.53e-06	2.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—pancreatic cancer	2.27e-06	2.31e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.07e-06	2.1e-05	CbGpPWpGaD
